Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
1.630
+0.110 (7.24%)
Nov 22, 2024, 4:00 PM EST - Market closed
LIXT Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
3.67M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sonoma Pharmaceuticals | 13.55M |
Genetic Technologies | 6.45M |
China Pharma Holdings | 5.54M |
Cyclerion Therapeutics | 194.00K |
Azitra | 97.50K |
LIXT News
- 2 months ago - LIXTE Receives U.S. Patent Issue Notification for Immune Oncology - GlobeNewsWire
- 3 months ago - First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company - GlobeNewsWire
- 3 months ago - LIXTE Biotechnology Provides Update On Recent Activities and Developments - GlobeNewsWire
- 3 months ago - LIXTE Biotechnology Holdings to Present at Two Investor Conferences - GlobeNewsWire
- 3 months ago - Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event - Accesswire
- 5 months ago - LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial - GlobeNewsWire
- 5 months ago - LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial - GlobeNewsWire
- 6 months ago - Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System - GlobeNewsWire